⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SGMO News
Sangamo Therapeutics, Inc. Common Stock
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
globenewswire.com
SGMO
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
globenewswire.com
SGMO
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
globenewswire.com
SGMO
Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals
globenewswire.com
NVS
GILD
BMY
REGN
CRSP
NTLA
EDIT
BBIO
AZN
SGMO
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
globenewswire.com
SGMO
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
globenewswire.com
SGMO
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
globenewswire.com
SGMO
Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight
prnewswire.com
NVO
ULTX
SGMO
PFE
BMN
SNY
CHGC
RHHBY
ALNY
BIIB
BAY
TSEM
CSL
HEMA
LFB
OCT
SOBI
ASC
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
globenewswire.com
SGMO
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
globenewswire.com
SGMO